May 16, 2016 (Shareholders Foundation) - An investigation for investors, who currently hold Sorrento Therapeutics Inc (NASDAQ:SRNE) shares, was announced whether a takeover of Sorrento Therapeutics Inc would be unfair.

The investigation by a law firm is at an early stage and concerns whether a potential takeover would be unfair to NASDAQ:SRNE investors.

Sorrento Therapeutics Inc reported that its annual Total Revenue rode from $0.46 million in 2013 to $4.59 million in 2015 while its Net Loss increased from $21.91 million in 2013 to $45.81 million in 2015.

Shares of Sorrento Therapeutics Inc (NASDAQ:SRNE) declined from as high as $23.51 per share to $4.50 per share in February 2016.

On May 9, 2016, Sorrento Therapeutics Inc (NASDAQ:SRNE) announced that early this year it engaged financial advisors to assist the company in exploring and evaluating strategic alternatives to maximize shareholder value.

Then on May 16, 2016, Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced that its partner, Mabtech Ltd., has successfully completed a combined Phase 2 & 3 clinical study in China for STI-004, a biosimilar antibody for Omalizumab (Xolair). Sorrento Therapeutics said that STI-004 met its primary endpoint in a multicenter, randomized, double-blind, placebo-controlled clinical trial.

However, given that at least one analyst has set the high target price for NASDAQ:SRNE shares at $30.00 per share, the investigation a law firm concerns whether the Sorrento Therapeutics board of Directors will undertake an adequate sales process, will adequately shop the company before entering into any transaction, will maximize shareholder value by negotiating the best price, and will act in the shareholders' best interests in connection with a proposed sale.